CDKN2A and cancer: CDKN2A is affected in about 10% of all cancers with the highest prevalence of alterations observed in lung adenocarcinoma, pancreatic adenocarcinoma, conventional glioblastoma multiforme, cutaneous melanoma, and bladder urothelial carcinoma [220–224].